Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis
TALANTA, cilt.80, sa.5, ss.1846-1848, 2010 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 80 Sayı: 5
- Basım Tarihi: 2010
- Doi Numarası: 10.1016/j.talanta.2009.10.032
- Dergi Adı: TALANTA
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1846-1848
- Anahtar Kelimeler: NTBC, Tyrosinemia, MEKC, Capillary electrophoresis, Metabolic disorder, 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE, PLASMA
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
Hereditary tyrosinemia type I is a serious metabolic disorder leading to liver failure 2-(2-Nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is a relatively new drug which is used to prevent the accumulation of toxic metabolites in patients with hereditary tyrosinemia type I. In the present study, we have developed a new, simple, fast, and cost-effective capillary electrophoresis method for the quantitative monitoring of this drug in serum samples. Micellar electrochromatographic separation of NTBC was performed using 20 mmol/L phosphate and 40 mmol/L sodium dodecylsulfate (SOS) at pH 12 as running electrolyte. Separation of NTBC was achieved in around 4 min. Reproducibilities of migration times and corrected peak areas of NTBC (as R.S.D %) were found as 073 and 1.99, respectively. The detection limit was 3.17 and the quantification limit was 10.6 mu mol/L. for NTBC using UV detection at 278 nm The utility of the method was demonstrated by the detection of NTBC in serum samples from patients with hereditary tyrosinemia type I using this drug. (C) 2009 Elsevier B.V. All rights reserved.